28bio is committed to promoting transparency, integrity, and objectivity in research and business practices. In compliance with applicable regulations, this Financial Conflict of Interest (FCOI) Policy ensures that financial interests do not improperly influence research or decision-making.

1. Disclosure of Financial Interests

All employees, researchers, and collaborators must disclose any significant financial interests (SFI) that could directly or indirectly affect 28bio’s business, research, or regulatory decisions.

2. Review & Management of FCOI

Disclosed financial interests will be reviewed by an appointed committee to determine if a conflict exists. If a conflict is identified, a management plan will be implemented to mitigate any potential influence on research integrity or business operations.

3. Training Requirements

Individuals engaged in research must complete FCOI training prior to participation and renew their training every four years or when policy updates occur.

4. Reporting Obligations

28bio will report identified FCOIs to applicable regulatory bodies as required by law, including funding agencies such as the NIH, ensuring compliance with federal guidelines.

5. Enforcement & Sanctions

Failure to disclose financial interests or comply with management plans may result in corrective actions, including termination of employment, loss of research privileges, or legal consequences.

For any questions or to disclose a potential financial conflict of interest, contact 28bio Investor Relations at investor@28bio.com

Financial Conflict of Interest Policy

1. Disclosure of Financial Interests

2. Review & Management of FCOI

3. Training Requirements

4. Reporting Obligations

5. Enforcement & Sanctions

Financial Conflict of Interest Policy